BACKGROUND Despite ethical imperatives, informing research participants about the results of the studies in which they take part is not often performed. This is due, in part, to the costs and burdens of communicating with each participant after publication of the results. METHODS Following the closeout and publication of a randomized clinical trial of saw palmetto for treatment of symptoms of...

Benign prostatic hyperplasia (BPH; Pic. 1) is characterized by increased size of the prostate leading to difficulties with passing the urine. The cells of prostate may increase in numbers (hyperplasia) or in size (hypertrophy) resulting in larger size of prostate. As result, prostatic nodules form in the transition zone of the prostate, which is the area where the prostate is surrounding the ur...

In 1990-2002, the authors conducted a population-based cohort study of 2,447 Caucasian men in Olmsted County, Minnesota, to determine whether daily users of nonsteroidal antiinflammatory drugs (NSAIDs) were at lower risk than nondaily NSAID users of developing benign prostatic hyperplasia. Participants completed validated questionnaires during a home visit, including information about daily NSA...

Abstract Background Benign prostatic hyperplasia (BPH) is a common disease which causes various health problems for elderly men such as urinary retention, recurring tract infection and bladder stones. The aim of this study to evaluate the therapeutic effects Juniperus communis L . seed extract (JCS) on BPH in male Wistar rats. Methods To end, 30 rats were divided into 5 groups ( N = 6): group 1...

Benign prostatic hyperplasia (BPH) is a common disease, not only in Asia but worldwide. The spectrum of disease may vary in differently region, but the basic pathophysiology is the same. To manage the disease, we need to define what it is, before the diagnosis. Management would be according to the basic fundamentals of good clinical practice. That is, whatever we do is for the benefit of the pa...

and commentary also appear in ACP Journal Club. Therapeutics EBM Volume 8 May/June 2003 83 www.evidence-basedmedicine.com group.bmj.com on August 27, 2017 Published by http://ebm.bmj.com/ Downloaded from

'UroLift' has emerged as a new minimally-invasive nonablative surgical technique for benign prostatic hyperplasia (BPH). We discuss the procedure, cost, evidence, advantages and disadvantages of this procedure. It is a novel technology suitable for a selected group of patients that allows for a bespoke treatment for men with BPH.

Symptomatic benign prostatic hyperplasia (BPH) occurs in one third of men over the age of 65 years. With an increase in the ageing population of Hong Kong, the number of men suffering from BPH is expected to increase in the next decade. These men will live longer, enjoy a better quality of life, and receive more comprehensive medical care for the remainder of their active lives than the previou...

Our treatment strategies for benign prostatic hyperplasia (BPH) have changed, with new insights into the pathophysiology of the disease, new clinical trials, and surgical advances. We present an update on treatment options and a diagnostic and treatment algorithm for this condition.

BACKGROUND Whereas geographical variations in intervention rates are well recognized, little is known about their implications for patient selection. This study looks at how the relative probability of being treated in different regions within England vary with a person's need for treatment, and whether higher intervention rates are associated with a greater probability of treatment at all leve...